

Executive Summary

Community Pharmacy-led Migraine Management Service Pilot

Organisations Involved:

Health Innovation North East and North Cumbria (HI NENC) and AbbVie Ltd

Project Summary:

AbbVie and HI NENC are working collaboratively to design, launch & evaluate a pilot that will test the value of a community pharmacy-led Migraine management service across the NENC region.

The objectives are to determine the extent to which the approach leads to improved management of migraine and the requirements for scaling this approach, with the goal of developing a replicable and scalable framework, should it prove effective.

Potential Benefits:

Anticipated Benefits for Patients

- Improved access to timely treatment for migraine in a primary care setting closer to the patient's home
- Enhanced quality, and experience of care

Anticipated Benefits for the NHS

- Reduced inappropriate referrals to secondary care
- Increased consultant capacity for complex neurological cases
- Reduced GP workload through pharmacist-led management for appropriate patients
- Improved data on headache service utilisation to inform planning and commissioning
- Clear understanding of the Digital requirements for pharmacy integration
- Framework for scalability

Anticipated Benefits for AbbVie

- Demonstrated partner of choice for opportunities to improve patient standards of care for migraine patients.

Start Date: April 2026. The project is anticipated to last 12 months

Contact: AbbVie Ltd AbbVie House Vanwall Business Park Vanwall Road Maidenhead Berkshire SL6 4UB

Email centralisationteam@abbvie.com

This executive summary is published on: www.abbvie.co.uk